Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits
Summary
Last week the New York-based biotech closed a $61 million Series B round of financing, cash that Baram says will help the company bring its gene editing approach into tests in humans some time next year. He adds that this approach enables Emendo to develop gene-editing therapies to edit any site on the genome and address dominant genetic diseases, which represent the majority of inherited disorders. Baram, whose background includes research in structural biology and protein engineering, says the scientists were trying to “expand the boundaries of gene editing.” The Emendo technology was developed in-house. The company’s drug pipeline includes a preclinical treatment for severe congenital neutropenia, a condition that leads to a deficiency of neutrophils, a type of white blood cell. The same month, South San Francisco-based Trucode Gene Repair closed a $34 million Series A round of funding to continue development of its technology, which uses a nanoparticle to deliver a DNA sequence to its target and potentially avoid the off-target effects that can occur with CRISPR editing.
Classifications
AskAI Classifications
LabelsLinked Companies
